BGPartner advised Novo Holdings, EQT, OrbiMed and SR One on $100 million Series C financing of Swiss biotech company Asceneuron, represented by Lenz & Staehelin, Geneva. The financing round was led by Novo Holdings with new
BGPartner advised Novo Holdings, EQT, OrbiMed and SR One on $100 million Series C financing of Swiss biotech company Asceneuron, represented by Lenz & Staehelin, Geneva. The financing round was led by Novo Holdings with new